iSERA Lifesciences Ltd (COVIDH) — shareholding pattern, promoter holding, financials and share price
About iSERA Lifesciences Ltd (COVIDH)
iSERA Lifesciences Ltd operates in the Computers - Software & Consulting industry, within the Information Technology sector. It trades on the NSE as COVIDH and on the BSE under scrip code 534920. Its ISIN is INE899M01020.
Incorporated in 1993, Covidh Technologies Ltd is engaged in IT/ITES business. [1]
Listed peers in Computers - Software & Consulting: Shradha AI Technologies Ltd, GenXAI Analytics Ltd, GTT Data Solutions Ltd, Secmark Consultancy Ltd, Focus Business Solution Ltd, R S Software (India) Ltd.
Valuation & Returns
At ₹144 a share, iSERA Lifesciences Ltd (COVIDH) was valued at a price-to-earnings ratio of 464.19x against an industry P/E of 17.23x and a price-to-book of 14.67x on a book value of ₹9.81 per share. Solomo computes return on equity of 3.15% and return on capital employed of 3.39% from filed results.
- P/E
- 464.19x
- Industry P/E
- 17.23x
- P/B
- 14.67x
- EPS (TTM)
- ₹0.31
- Book value / share
- ₹9.81
- ROE
- 3.15%
- ROCE
- 3.39%
- ROA
- 2.46%
- Debt / equity
- 0.2x
- Dividend yield
- 0%
- EBITDA margin
- 25.19%
- 52-week range
- ₹2.18 – ₹143.9
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2019In the year ended Mar 2019, iSERA Lifesciences Ltd (COVIDH) reported revenue of ₹25.69 crore and net profit of ₹-0.04 crore. That compares with revenue of ₹33.57 crore and net profit of ₹0.01 crore in Mar 2018. Figures are consolidated, as filed with the exchanges.
In the quarter ended Jun 2019, revenue was ₹1.11 crore and net profit ₹-0.06 crore (consolidated).
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2018 | Mar 2019 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 35.89 | 11.06 | 25.5 | 33.57 | 25.69 |
| Net profit (₹ cr) | 0.11 | 0.13 | -13.42 | 0.01 | -0.04 |
| EPS (₹) | 0 | 0 | -0.49 | 0 | 0 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | - | - | - | -23.47% |
| Profit growth | - | - | - | -500.00% |
| Stock price CAGR | 47% | 173% | 319% | - |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 58.63% of iSERA Lifesciences Ltd (COVIDH) (unchanged from the previous quarter). Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Dec 2012.
Largest disclosed public shareholders in Jun 2026: Neville Maneckji 4.31%, GANAPA NARSI REDDY 3.57%, KUNAAL DEEPAK AGASHE 1.19%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 58.63% | - | - | - | 41.37% |
| Mar 2026 | 58.63% | - | 0% | 0% | 41.37% |
| Dec 2025 | 3.57% | - | - | - | 96.43% |
| Sep 2025 | 92.76% | 100% | - | - | 7.24% |
| Jun 2025 | 92.76% | - | - | - | 7.24% |
| Mar 2025 | 92.76% | - | - | - | 7.24% |
| Dec 2024 | 26.35% | - | - | - | 73.65% |
| Sep 2024 | 26.35% | - | - | - | 73.65% |